Nkarta, Inc. (NKTX) Dividend History

Nkarta, Inc. is a biotechnology company focused on developing allogeneic CAR NK (natural killer) cell therapies for cancer treatment. Leveraging its proprietary cell engineering platform, Nkarta aims to create off-the-shelf immunotherapies to improve efficacy and safety for patients with various cancers.

1150 Veterans Boulevard, South San Francisco, CA, 94080
Phone: (925) 407-1049
Website: https://www.nkartatx.com

Dividend History

Nkarta, Inc. currently does not pay dividends

Company News

  • Nkarta to Participate in an April Investor Conference

    Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.

    GlobeNewswire Inc.
  • Why Nkarta Stock Is Soaring Today

    Nkarta's stock surged 11.1% after Raymond James upgraded the stock to a strong buy, citing the company's strong cash position and the potential of its lead candidate NKX019 in treating autoimmune diseases.

    The Motley Fool
  • Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

    Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.  CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024.  Century Therapeutics plans to pursue additional autoimmune disease indication regulatory filings in 2024.  The company announced a $60 million private placement to support Century Therapeutics’ increased R&D activities in autoimmune diseases.  Century will issue approximately 15.87 million shares at $3.78. The company estimates that its cash, cash equivalents, and investments will support operations into 2026. Concurrently, Century announced pipeline and ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: IPSC
  • Penny Stocks To Buy Now? 4 To Watch Before 2024

    Are these penny stocks a buy before next year? The post Penny Stocks To Buy Now? 4 To Watch Before 2024 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: DCTH TOI WVE
  • All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy

    Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Zacks Investment Research
Page data last updated 07/22/2025 22:04:34 UTC